Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Maryland, Baltimore
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age 18-75 years old.
Acute high-risk or intermediate-risk PE diagnosed by CTPA within 28 days prior to enrollment
You may not be if
Contraindication for anticoagulation
Allergy or contraindications to Macitentan or any other endothelin receptor antagonist.
Surgical interventions to treat PE including catheter-directed thrombolysis, catheter-based thrombectomy, or surgical pulmonary embolectomy.
Known inherited or acquired hypercoagulable states
History of pulmonary embolism prior to index PE
History of pulmonary hypertension including Group 1 (Primary pulmonary hypertension), Group 2 (secondary to left heart disease), Group 3 (secondary to lung disease), Group 4 (Chronic thromboembolic pulmonary hypertension)
Severe chronic obstructive pulmonary disease
Severe uncontrolled asthma
Pregnancy or fertility treatment
Breastfeeding
Life expectancy is less than 6 months
History of radiation therapy to the chest
Current or previous use within 90 days of an endothelin-receptor antagonist, prostacyclin analogue, phosphodiesterase type 5 inhibitor, or nitric oxide donor.
Severe allergic reaction to iodine contrast
Subjects receiving CYP3A4 and CYP2C9 inhibitors or inducers such as rifampin, ritonavir, fluconazole, amiodarone
Not able to read or understand the English language
